Pilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating Hydrocephalus

Hydrocephalus Clinical Trial

Official title:

US Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Communicating Hydrocephalus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05501002
• Other study ID #: CLIN-0029
• Status: Terminated
• Phase: N/A
• Start date: September 15, 2022
• Est. completion date: September 15, 2023

Study information

• Verified date: February 2024
• Source: CereVasc Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

Description:

This is a prospective, multi-center, open label, pilot study of the eShunt® System. The study population consists of patients with post-aneurysmal subarachnoid hemorrhage (SAH) treated for increased intracranial pressure (ICP) resulting in symptomatic hydrocephalus using an external ventricular drain (EVD) to facilitate CSF drainage and who cannot be "weaned" from the EVD after the hemorrhagic event.

After completion of the procedure to place the eShunt® device, the ICP will be monitored and recorded for up to 48 hours. Subjects will then return for follow-up visits that include standard neurological evaluations at 30, 60, 90, 180, and 365 days postimplantation; imaging will also be acquired at 30, 90 and 365 days after implant. Subjects will continue to attend follow-up visits every 180 days thereafter until the study is closed or up to 5 years post-implantation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: September 15, 2023
• Est. primary completion date: September 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Patient is = 21 years old

• Patient or legally authorized representative is able and willing to provide written informed consent

• Post-aneurysmal SAH with Hunt and Hess Grades I-IV with EVD in place for at least 7 days with the need for a permanent CSF shunt determined through a failed EVD clamping trial defined as:

1. Post-clamping ICP of > 20 cmH2O for 15 minutes, or

2. Post-clamping ICP > 25 cmH2O for < 15 minutes with patient intolerance to EVD clamping, or

3. Significant radiographic signs of increasing ventriculomegaly, or

4. Neurological decline attributable to ventriculomegaly and requiring CSF diversion

• Clinical signs and symptoms of communicating hydrocephalus

• Neurologically stable without evidence of severe vasospasm

• Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by subject screening committee (SSC)

• Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC

Exclusion Criteria:

• Presence of gross blood in CSF

• Signs or symptoms of obstructive hydrocephalus

• Active systemic infection or infection detected in CSF

• Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus

• Hypersensitivity or contraindication to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available

• Occlusion or stenosis of the internal jugular vein

• Venous distension in the neck on physical exam

• Medical conditions associated with prolonged elevation of jugular venous pressure, including jugular vein stenosis or stricture, right sided heart failure, cirrhosis of the liver, arterial venous fistulas in the arm for dialysis purposes, or an arterial venous fistula or malformation in the neck or brain

• Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram

• History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency

• Stroke or transient ischemic attack within 180 days of eShunt Procedure

• Presence of a deep vein thrombosis superior to the popliteal vein

• International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)

• Presence of a posterior fossa tumor or mass

• Life expectancy < 1 year

• Currently participating in another investigational drug or device trial that could conflict with study data collection or follow-up

• Pregnant

• Unwilling or unable to comply with follow-up requirements

Related Conditions & MeSH terms

• Hydrocephalus
• Hydrocephalus, Communicating

Intervention

Device:
• eShunt® Implant
The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.

Locations

Country	Name	City	State
United States	Yale University	New Haven	Connecticut
United States	Montefiore Medical Center Department of Neurosurgery	New York	New York

Sponsors (4)

Lead Sponsor	Collaborator
CereVasc Inc	AlvaMed, Inc., Bioscience Consulting, Inc., Simplified Clinical Data Systems, LLC

Country where clinical trial is conducted

United States, 

References & Publications (2)

Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. — View Citation

Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in ICP	At 24 to 48 hours after eShunt Implant deployment (with EVD remaining clamped) an ICP measurement that indicates: ICP below 20 cmH2O with no periods longer than 15 minutes above 20 cmH2O; No episodes of ICP above 25 cmH2O with associated symptoms	24-48 hours after eShunt Implant placement
Secondary	Occurrence of Serious Adverse Events	The number of device and/or procedure-related serious adverse events (SAEs) after the implant procedure will be calculated.	90 days post procedure
Secondary	Incidence of clinically significant changes in Computed Tomography Imaging (CT/CTA) from baseline.	Clinically significant changes from baseline CT images will be summarized	1 year post procedure
Secondary	Number of participants with clinically significant changes in physical and neurologic examination assessments from baseline	Clinically significant changes from baseline physical examination and neurologic examination assessments will be summarized	1 year post procedure
Secondary	Summary of Adverse Events	Tabulation of all Adverse Events collected in the study.	90 days post procedure and at study completion
Secondary	Changes in Modified Rankin Scale Scores	Changes in Modified Rankin Scale scores from baseline will be summarized.	1 year post procedure
Secondary	Number of subjects requiring conversion to conventional CSF shunt	Evaluate the need for CSF diversion by conventional CSF shunt insertion within 12 months after eShunt Implant deployment	1 year post procedure